Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710004, China.
Clinical Research Center of Shaanxi Province for Dental and Maxillofacial Diseases, Xi'an, Shaanxi Province, 710004, China.
BMC Endocr Disord. 2024 Mar 13;24(1):36. doi: 10.1186/s12902-024-01565-w.
Prior studies reported that elevated asprosin level was associated with obesity in adults and animal models. However, the relationship between asprosin level and children with obeisty remains controversial. The aim of our analysis was to systematically review available literatures linking asprosin and children with obesity for a comprehensive understanding of the relationship between circulating asprosin level and obesity in children.
Eight databases were gleaned for studies published up to January 2024. Standard mean difference with 95% confidence interval (CI) and Fisher's Z transformation was calculated to evaluate the relationship between asprosin level and children with obesity using the Review Manager 5.4 Software. Other indicators were measured via mean difference with 95% CI.
Six observational studies were included both in systematic review and meta-analysis. The current evidence indicated that no significant difference was observed in the level of circulating asprosin between the children with and without obesity (SMD = 0.37; 95% CI:-0.22-0.95, p = 0.22). However, Fisher's Z transformation suggested the positive association of circulating asprosin levels and clinical index measuring the degree of obesity: total cholesterol (Fisher's Z: 0.11, 95% CI: 0.02-0.20, p = 0.02).
Circulating asprosin level was not independently related to childhood obesity currently. More rigorous longitudinal researches were required to disentangle the causations. However, the positive association of asprosin levels and total cholesterol indicated that asprosin might get involved in the lipid-metabolism of childhood obesity, asprosin might be a prospective bio-index and targeted treatment of total cholesterol metabolism besides the role of glucogenic and orexigenic.
Prospero ID: CRD42023426476.
先前的研究表明，天门冬氨酸升高与成年人和动物模型中的肥胖有关。然而，天门冬氨酸水平与肥胖儿童之间的关系仍存在争议。我们分析的目的是系统地回顾现有的文献，将天门冬氨酸与肥胖儿童联系起来，以全面了解循环天门冬氨酸水平与儿童肥胖之间的关系。
从八个数据库中筛选出截至 2024 年 1 月发表的研究。使用 Review Manager 5.4 软件计算标准均数差（SMD）和 95%置信区间（CI）以及 Fisher's Z 变换，以评估天门冬氨酸水平与肥胖儿童之间的关系。其他指标则通过 95%CI 计算均数差进行测量。
纳入了系统评价和荟萃分析的 6 项观察性研究。目前的证据表明，肥胖儿童和非肥胖儿童的循环天门冬氨酸水平没有显著差异（SMD=0.37；95%CI：-0.22-0.95，p=0.22）。然而，Fisher's Z 变换表明，循环天门冬氨酸水平与临床指标（衡量肥胖程度）之间存在正相关：总胆固醇（Fisher's Z：0.11，95%CI：0.02-0.20，p=0.02）。
目前，循环天门冬氨酸水平与儿童肥胖症无独立相关性。需要更严格的纵向研究来理清因果关系。然而，天门冬氨酸水平与总胆固醇之间的正相关表明，天门冬氨酸可能参与了儿童肥胖症的脂质代谢，除了具有生糖和食欲刺激作用外，天门冬氨酸可能成为总胆固醇代谢的一个有前景的生物指标和靶向治疗靶点。
Prospéro 注册号：CRD42023426476。
